Drug Neurology

Vyvgart Hytrulo

Payments companies reported to CMS as associated with Vyvgart Hytrulo. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$2.9Massociated payments (2023-2025)
7,229clinicians with associated payments
1company reporting

By year

2023 $133K
2024 $1.3M
2025 $1.5M

Payments reported as associated with Vyvgart Hytrulo, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Neurology (Psychiatry & Neurology) $1.5M
Neuromuscular Medicine (Psychiatry & Neurology) $407K
Family $111K
Rheumatology $109K
Clinical Neurophysiology $60K
Neurology With Special Qualifications In Child Neurology $57K

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Vyvgart Hytrulo

These are the largest totals companies reported as associated with Vyvgart Hytrulo. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
Jeffery Allen Minneapolis, MN Neurology (Psychiatry & Neurology) $103,392.24
Samir Macwan Rancho Mirage, CA Neuromuscular Medicine (Psychiatry & Neurology) $85,541.79
Dinesh Khanna Ann Arbor, MI Rheumatology $65,450.00
Barry Vaught Crab Orchard, WV Neurology (Psychiatry & Neurology) $64,062.08
Jeffrey Rosenfeld Fresno, CA Neuromuscular Medicine (Psychiatry & Neurology) $50,222.70
Mark Bromberg Salt Lake City, UT Neurology (Psychiatry & Neurology) $50,023.30
Nicholas Silvestri Buffalo, NY Neuromuscular Medicine (Psychiatry & Neurology) $49,673.41
Mario Vukic Hackensack, NJ $45,054.58
Charulatha Nagar Lake Forest, IL Neurology (Psychiatry & Neurology) $41,381.28
John Hemphill Savannah, GA Neurology With Special Qualifications In Child Neurology $40,602.81

Prescribed Vyvgart Hytrulo?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.